MRVI — Maravai Lifesciences Holdings Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapNeutral

Annual income statement for Maravai Lifesciences Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	284	799	883	289	259
Cost of Revenue
Gross Profit	204	659	714	140	108
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	172	245	309	321	498
Operating Profit	112	555	574	-31.6	-239
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	81.7	531	551	618	-261
Provision for Income Taxes
Net Income After Taxes	78.8	469	491	-138	-260
Minority Interest
Net Income Before Extraordinary Items
Net Income	92.2	182	220	-119	-145
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	76.9	402	426	-119	-145
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.272	1.53	1.74	-0.72	0.222